ABOS Acumen Pharmaceuticals Inc
1,107
$3.25
4.41%
| Watchers | 1,107 |
| 52-Wk Low | $1.81 |
| 52-Wk High | $11.31 |
| Market Cap | $195.26M |
| Volume | 252.00 |
| 52-Wk High | $11.31 |
| 52-Wk Low | $1.81 |
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Expected to Earn Q2 2024 Earnings of ($0.26) Per ShareZolmax • about 2 months ago
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Free Report) - Equities research analysts at HC Wainwright issued their Q2 2024 EPS estimates for shares of Acumen Pharmaceuticals in a note issued to...
Share to Feed
Acumen Pharmaceuticals (NASDAQ:ABOS - Get Free Report) and Inhibrx (NASDAQ:INBX - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two...
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS - Get Free Report) saw a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 1,020,000 shares, an...
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS Free Report) Equities research analysts at HC Wainwright issued their Q1 2024 earnings per share (EPS) estimates for Acumen Pharmaceuticals...
Investors might want to bet on Acumen Pharmaceuticals, Inc. (ABOS), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates...
Related Stocks: NAS:ABOS...
Acumen Pharmaceuticals (NASDAQ:ABOS Get Free Report)s stock had its buy rating restated by investment analysts at HC Wainwright in a research report issued to clients and...
Initiation of a Phase 2 study, ALTITUDE-AD, to investigate sabirnetug (ACU193) for the treatment of early Alzheimer's disease expected in the first half of 2024 Initiation of a Phase 1 study to...
Acumen Pharmaceuticals, Inc. 2023 Q4 - Results - Earnings Call Presentation...